Genecast MRD – Comprehensive is our NGS-based large panel MRD test, which detects MRD using our MinerVa platform and provides postoperative prognosis, risk assessment of recurrence and efficacy evaluation of adjuvant treatment for multiple types of cancer (except for lung cancer and colorectal cancer).
It uses a fixed panel of 769 genes to detect personalized tumor gene mutations in DNA extracted from FFPE tissue samples and ctDNA extracted from liquid biopsy samples of the patient and provides postoperative monitoring of the patient’s MRD status to measure the dynamic changes in the tumor load.
Cancer patients can periodically be assessed by conducting Genecast MRD- Comprehensive to detect MRD, monitor recurrence and evaluate the efficacy of adjuvant treatment.